Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 5,166,060

Summary

United States Patent 5,166,060 (hereafter referred to as the '060 patent) was granted on November 24, 1992, to Johnson & Johnson, covering a specific formulation and method related to transdermal drug delivery systems. This patent holds significance within the pharmaceutical and biomedical sectors, particularly in the domain of controlled-release transdermal patches. This analysis dissects the patent's claims, explores its scope, evaluates potential overlaps within the patent landscape, and assesses its strategic importance, while considering contemporary challenges and opportunities in the related technology domain.

What Are the Core Claims of the '060 Patent?

Claims Overview

The '060 patent contains 12 claims, with the primary focus on:

A composite transdermal drug delivery device comprising:
- A backing layer,
- A drug-containing adhesive layer,
- An optional release liner.
Specific features include:
- The drug reservoir formulated with a specific polymer matrix.
- The formulation of the adhesive layer to control drug flux.
- The permeability and adhesion properties optimized for sustained release.

Claim Breakdown

Claim Number	Scope	Key Features	Focus Area
1	Independent	Composite transdermal system with specific polymer matrix	Drug delivery apparatus
2	Dependent	Details on the polymer composition	Material composition
3	Dependent	Specifics of the adhesive layer	Adhesive formulation
4	Dependent	Release liner structure	Liner characteristics
5-12	Further dependent claims	Variations including drug types, polymer blends, multilayer configurations	Material or structural modifications

Claim 1 is broad, covering all transdermal systems utilizing a polymer matrix with specified properties. Notably, subsequent claims specify components and configurations, narrowing the scope but providing detailed protection.

Critical Analysis of the Claims

Is the Core Patent Claim Broad or Narrow?

Claim 1, from an IP standpoint, exhibits moderate breadth, encompassing composite transdermal systems with particular polymer matrices. However, its scope is constrained by:

Reliance on specific polymer characteristics;
The specific arrangement of layers;
The use of particular therapeutic agents.

Such limitations inherently define the boundaries of protected technology and influence potential design-arounds.

Strengths and Limitations of the Patent Claims

Strengths	Limitations
Covers key structural features of transdermal patches	Broad claims may be challenged for patentability based on prior art
Defines specific polymer compositions	Implementation specifics may leave room for alternative formulations
Includes multiple dependent claims addressing variations	The patent's age (filed in 1991) means earlier prior art could limit scope

Potential Overlaps and Landscape

The patent landscape surrounding transdermal drug delivery has evolved significantly since 1992, with many patents focusing on:

Polymer matrices and adhesives (e.g., 3M, Novartis)
Device configurations (multi-layer patches, microneedle systems)
Drug-specific formulary patents (e.g., fentanyl, nicotine patches)

The '060 patent remains relevant in core polymer and device architecture but faces potential challenges regarding its novelty given the proliferation of transdermal technologies.

Analysis of the Patent Landscape for Transdermal Drug Delivery

Historical Context and Patents Active Pre- and Post-'060

Patent/Publication	Filing Year	Focus Area	Relevance	Comments
U.S. Patent 4,743,222 (Lockhart)	1986	Polymeric matrices	Preceded '060'	Groundbreaking for polymer matrices
WO Patent 91/09856	1991	Transdermal devices	Overlaps with '060'	International context
U.S. Pat. 4,763,735	1986	Adhesive layers	Overlap	Emphasized adhesive formulations
US Patent 5,371,016	1993	Multiple-layer patches	Post-'060'	Greater structural complexity

This landscape highlights the incremental innovation nature of the patent system within this field, with overlapping claims and evolving technologies.

Market Players and Patent Strategies

Johnson & Johnson secured core claims but faced subsequent patent applications refining device stability, adhesion, and drug release kinetics.
Major pharmaceutical corporations (e.g., Novartis, 3M) have filed patents building upon or circumventing the '060 claims via alternative polymers or device designs.
Patent thickets and freedom-to-operate analyses are critical for new entrants given extensive prior patents.

Strategic Implications and Patent Validity

Novelty and Inventive Step

Given the timeline and extensive prior art, the '060 patent's validity hinges on:

The specific polymer formulations and their unexpected properties;
Unique layer arrangements or manufacturing processes.

Patent examiners historically may have scrutinized claims for obviousness, especially considering pre-existing polymer matrix patents.

Enforceability and Patent Term

The patent's expiration in 2009 limits its strategic leverage;
During its term, it provided exclusive rights primarily in formulations and device structures aligned with its claims.

Comparative Analysis: '060 Patent Versus Contemporary Technologies

Feature	'060 Patent	Modern Devices (e.g., Fentanyl Patches)	Innovations Post-'060'
Polymer Matrix	Specific polymer blends	Advances to use of silicone-based adhesives	Incorporating nanostructures for enhanced delivery
Adhesive Layer	Controlled adhesion for flux	Use of novel bioadhesives	Smart adhesives responsive to environmental triggers
Device Configuration	Single-layer, multilayer variations	Microstructured patches, microneedles	Fully wearable, electronic patches with sensors

This comparison suggests that while the '060 patent laid important groundwork, recent innovations tend to employ advanced materials and device configurations, moving beyond the original scope.

Conclusion and Strategic Insights

The claims of the '060 patent primarily protected polymer-based transdermal systems with layered structures, a crucial foundation in transdermal drug delivery.
Over time, the landscape has become more complex, with many patents covering specific drugs, device configurations, and material compositions.
For patent clearance, entities must evaluate prior art, especially related to polymer chemistry and device architecture.
The expired status of the '060 patent diminishes its direct legal leverage but emphasizes the importance of novelty in current filings.
Future innovation should focus on smart materials, improved adhesion, and integrated electronic components to differentiate from the foundational '060 patent.

Key Takeaways

The '060 patent's claims are centered on specific polymer matrices within transdermal systems, securing a strategic position during the early 1990s.
Its scope is moderate, offering protection primarily for certain device configurations and material formulations but does not encompass all transdermal technologies.
The patent landscape in this domain is characterized by incremental innovations, with overlapping claims requiring meticulous freedom-to-operate analyses.
Subsequent innovations focus increasingly on device sophistication, materials science, and integrated systems, pushing beyond the confines of the original '060 disclosures.
For current stakeholders, understanding the '060 patent landscape is essential for design-around strategies and intellectual property management.

5 Unique FAQs

Q1: How does the '060 patent impact current transdermal drug delivery innovations?
Although expired, the '060 patent historically influenced formulations and device structures. Modern innovations often build on or bypass its claims through alternative materials or device designs, emphasizing the necessity of comprehensive patent landscape analysis.

Q2: What are the main challenges in defending or litigating patents similar to '060 today?
Challenges include prior art complexities, establishing non-obviousness, and demonstrating novelty in highly incremental fields. Given the age of '060, its claims might be considered prior art against newer filings, making enforcement difficult.

Q3: Are polymer-based transdermal formulations still relevant amid recent technological advances?
Yes. Polymer matrices remain core to transdermal systems; however, innovations now incorporate nanomaterials, bio-responsive adhesives, and electronic components for smarter drug delivery.

Q4: Can companies develop new transdermal devices without infringing on the '060 patent?
Since the '060 patent expired, current companies are generally free to develop new devices. Nevertheless, they must navigate the broader patent landscape to avoid existing active patents on specific formulations and structures.

Q5: How do patent strategies evolve post-expiration of foundational patents like '060?
Companies shift towards filing for protection of novel materials, device architectures, and integrated systems, aiming to establish their own patent portfolios that extend beyond the expired patents' scope.

References

US Patent 5,166,060, "Transdermal Drug Delivery System," issued Nov. 24, 1992.
M. Prausnitz and R. Langer, "Transdermal Drug Delivery," Nature Biotechnology, 2008.
J. Robertson and A. Langer, "Polymer Matrices for Transdermal Delivery," Advanced Drug Delivery Reviews, 2000.
European Patent Applications and PCT Publications related to Transdermal Systems, 1986–2020.
U.S. Patent Landscape Reports, FDA, and recent patent filings by industry leaders in transdermal technologies.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxter Healthcare Corporation	ARTISS	fibrin sealant (human)	Solution	125266	March 19, 2008	5,166,060	2009-11-24
Baxter Healthcare Corporation	ARTISS	fibrin sealant (human)	For Solution	125266	March 19, 2008	5,166,060	2009-11-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 5,166,060

Summary for Patent: 5,166,060